NSCLC Survival Associated With Institutional Differences in Quality of Care

Share this content:
Institutional-level differences in the quality of care of patients with NSCLC are associated with differences in stage-stratified and overall survival.
Institutional-level differences in the quality of care of patients with NSCLC are associated with differences in stage-stratified and overall survival.

Institutional-level differences in the quality of care of patients with NSCLC are associated with differences in stage-stratified and overall survival (OS), according to results presented at the International Association for the Study of Lung Cancer (IASLC) 17th Annual World Conference on Lung Cancer in Austria.1

Researchers analyzed stage-stratified and OS of patients at different institutions to quantify institutional differences in quality measures and estimate their relative survival impact. Based on the results, they identified the most important targets for improvement efforts.



The researchers grouped National Cancer Data Base (NCDB) institutions according to their American College of Surgeons Commission on Cancer (COC) accreditation and categorization. Categories included: Community Cancer Program (CCP), Comprehensive Community Cancer Program (CCCP), Teaching Research Program (TRP), and NCI Program/Network (NCIP).

They examined data on quality parameters for resections performed within each category of institution for patients with stage I through stage IIIA NSCLC in the NCDB from 2004-2013. Of 125,408 eligible patients, 8% received surgery at CCP, 52% at CCCP, 28% at TRP, and 12% at NCIP. 

The researchers found “striking differences” in the quality and accuracy of NSCLC pathologic nodal staging between the different categories of COC-accredited treatment facilities. They also found significantly higher quality stage-stratified OS in institutions with higher quality staging. The difference in survival disappeared among patients who did not have examination of lymph nodes, who they wrote “arguably have similarly bad quality pathologic nodal staging.”

Adjusting for other measures of pathologic nodal staging quality did not, however, eliminate the survival disparity among institutions.

RELATED: Researchers Find Modest Success in Tobacco Cessation Program

The researchers recommended further investigation of the practice differences among institutions to better understand how institutional differences affect survival following resection for NSCLC.

Reference

  1. Osarogiagbon RU, Lin CC, Smeltzer MP, Jemal A. Institutional-based differences in the quality and outcomes of US lung cancer resections. Paper presented at: International Association for the Study of Lung Cancer 17th World Conference on Lung Cancer; December 2016; Vienna, Austria. 

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs